

## **Product datasheet for SR320899**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## SMAD4 Human siRNA Oligo Duplex (Locus ID 4089)

#### **Product data:**

**Product Type:** siRNA Oligo Duplexes

Purity: HPLC purified

**Quality Control:** Tested by ESI-MS

Sequences: Available with shipment

**Stability:** One year from date of shipment when stored at -20°C.

# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

**Note:** Single siRNA duplex (10nmol) can be ordered.

**RefSeq:** <u>NM 005359</u>

UniProt ID: Q13485

Synonyms: DPC4; JIP; MADH4; MYHRS

Components: SMAD4 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 4089)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol

Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

**Summary:** This gene encodes a member of the Smad family of signal transduction proteins. Smad

proteins are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor (TGF)-beta signaling. The product of this gene forms homomeric complexes and heteromeric complexes with other activated Smad proteins, which then accumulate in the nucleus and regulate the transcription of target genes. This protein binds to DNA and recognizes an 8-bp palindromic sequence (GTCTAGAC) called the Smad-binding element (SBE). The protein acts as a tumor suppressor and inhibits epithelial cell proliferation. It may also have an inhibitory effect on tumors by reducing angiogenesis and increasng blood vessel hyperpermeability. The encoded protein is a crucial component of the bone morphogenetic protein signaling pathway. The Smad proteins are subject to complex regulation by post-translational modifications. Mutations or deletions in this gene have been shown to result in pancreatic cancer, juvenile polyposis syndrome, and

hereditary hemorrhagic telangiectasia syndrome. [provided by RefSeq, Aug 2017]





# Performance Guaranteed:

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).